THE BIRTH CONTROL AND BREAST CANCER LINK: WHAT THE RESEARCH ACTUALLY SAYS

The conversation about hormonal birth control and breast cancer risk has never been easy. For decades it has oscillated between dismissal and alarm, between doctors reassuring patients that the risk is negligible and social media content presenting the same data as evidence that the pill is as dangerous as smoking. Neither characterization is accurate. And neither serves women particularly well.

The research is real. The association is real. The risk is also genuinely modest, context-dependent, and reversible in ways that headlines rarely have room to explain. What women deserve is not a simplified number stripped of context but the full picture: what the studies actually found, what the numbers mean at the individual level, which formulations carry higher or lower risk, and how to weigh this information against the very real benefits that hormonal contraception also provides.

That is what this article attempts to offer.

What the Research Has Found

The association between hormonal contraceptive use and a small increased risk of breast cancer has been documented across multiple large studies spanning several decades and multiple countries.

The landmark 2017 Danish registry study tracked 1.8 million women aged 15 to 49 and found that current and recent users of hormonal contraceptives had a relative risk of breast cancer approximately 20 percent higher than non-users. A 2023 UK nested case-control study and meta-analysis published in PLOS Medicine examined nearly 10,000 women with breast cancer and 18,000 matched controls and found that both combined oral contraceptives and progestogen-only contraceptives were associated with a similar magnitude of elevated breast cancer risk, approximately 20 to 25 percent higher relative risk compared to non-users.

In 2025, a major Swedish study tracking more than two million teenage girls and women under 50 for over a decade, published in JAMA Oncology, found that women who had ever used hormonal contraception had a 24 percent higher relative risk of breast cancer than women who had never used hormonal birth control. The study also found meaningful differences between formulations, which will be discussed below.

These findings are consistent across populations, methodologies, and time periods. The association is not a fluke or an artifact of any single study. It is a real and replicable finding. The critical question is what it means in practice.

What Relative Risk Actually Means

A 20 to 24 percent increased relative risk sounds alarming until it is placed in the context of absolute risk, and this context is where most media coverage fails women significantly.

Breast cancer is still uncommon in young women, the primary demographic using hormonal contraception. In that context, the Swedish study's finding of a 24 percent elevated relative risk translates to an increase from approximately 54 to 67 breast cancer cases per 100,000 women per year. That is roughly 13 additional cases per 100,000 women annually, or approximately one additional case per 7,800 users of hormonal contraceptives per year.

To translate this further: for a 20-year-old who takes combined oral contraceptives for ten years, the absolute 10-year breast cancer risk increases from approximately 0.07 percent to approximately 0.09 percent. For a 30-year-old, it increases from approximately 0.49 percent to approximately 0.64 percent. These are real increases. They are also very small in absolute terms for the average woman at average baseline risk.

For women with elevated baseline risk, the picture changes. A woman with BRCA1 gene mutations who has a 20 percent ten-year breast cancer risk would see that risk rise to approximately 26 percent with combined oral contraceptive use. For women at higher baseline risk due to family history, genetic factors, or other variables, the added relative risk from hormonal contraception carries more absolute weight, and that conversation with a clinician becomes significantly more important.

Not All Formulations Carry Equal Risk

One of the most clinically relevant findings from recent research is that different hormonal contraceptive formulations appear to carry meaningfully different levels of risk, and this distinction is rarely communicated clearly to women.

The key variable appears to be the type of progestin used. A 2025 study published in JAMA Oncology found that hormonal contraceptives containing the progestin desogestrel, used in some combination pills and progestin-only pills, were associated with higher breast cancer risk than contraceptives containing levonorgestrel. This was particularly pronounced in progestin-only preparations. Formulations containing desogestrel and its metabolite etonogestrel, also used in some implants, carried the highest observed relative risks in the study, in the range of 1.18 to 1.22.

Levonorgestrel-containing methods showed lower but still present elevated risks. A 2024 study found a slightly higher breast cancer risk in people who used hormonal IUDs containing levonorgestrel compared to those who had never used hormonal birth control, though the absolute numbers remained small.

The 2023 PLOS Medicine study found similar magnitudes of risk between combined oral contraceptives and progestogen-only preparations, which challenged a previous assumption that progestogen-only methods were safer from a breast cancer perspective. This remains an active area of research and one where evidence is still accumulating and being refined.

The practical implication is that the conversation about contraceptive choice should include specific discussion of formulation, not just a blanket assessment of hormonal versus non-hormonal methods. Two different pills are not interchangeable from a risk perspective.

Duration and Timing Matter

The research consistently finds that the elevated risk is highest during current or recent use and declines after stopping hormonal contraception. Multiple studies show that after approximately five years without hormonal contraception, a woman's breast cancer risk returns to levels comparable to those of women who never used it. Some studies suggest the return to baseline takes up to ten years.

Duration of use also matters. Women who use hormonal contraceptives for longer periods show modestly higher relative risks than shorter-term users. A systematic review and meta-analysis published in ScienceDirect in 2025, examining cohort studies through September 2025, found dose-response evidence suggesting that risk increased with each additional year of hormonal contraceptive use, particularly beyond five years of continuous use.

This means that the risk profile for a woman who uses the pill for two years in her twenties is different from the risk profile for a woman who uses continuous hormonal contraception from adolescence through her late thirties. Duration is a meaningful variable that is worth including in any honest discussion of this topic.

The Benefits That Must Also Be Counted

An honest assessment of the birth control and breast cancer link requires holding the risk data alongside the equally real data on hormonal contraception's protective effects, because these exist and they are significant.

Hormonal contraceptives are associated with meaningfully reduced risks of ovarian and uterine cancers, and these protective effects persist for years after stopping. The risk of ovarian cancer in particular is reduced by approximately 30 to 50 percent in long-term users, and this protection continues for at least 30 years after discontinuation in some studies. Combined oral contraceptives also reduce the risk of endometrial cancer, ectopic pregnancy, pelvic inflammatory disease, and iron-deficiency anemia associated with heavy periods.

Beyond cancer risk, hormonal contraceptives are used by millions of women to manage endometriosis, polycystic ovary syndrome, severe dysmenorrhea, and other conditions for which they provide genuine therapeutic benefit. The Susan G. Komen Foundation puts it plainly: decisions about birth control should weigh any small increase in breast cancer risk against all benefits, including pregnancy prevention, reduction of other cancer risks, and management of other health conditions.

The risk of unintended pregnancy without contraception is approximately 85 percent over a year of unprotected sex. Unintended pregnancies carry their own health risks. The calculus for each woman will be different depending on her individual circumstances, values, and baseline risk profile.

Non-Hormonal Alternatives Worth Knowing

For women who, after understanding the full picture, wish to reduce their exposure to synthetic hormones, non-hormonal contraceptive options exist and deserve more mainstream discussion than they currently receive.

The copper IUD is the most effective non-hormonal long-acting reversible contraceptive available. It contains no hormones, works by creating a copper ion environment that is toxic to sperm, and is over 99 percent effective at preventing pregnancy. It does not carry the same breast cancer associations as hormonal methods and provides long-term protection that is immediately reversible upon removal.

Barrier methods including condoms and diaphragms, used consistently and correctly, provide meaningful pregnancy prevention without hormonal exposure. Fertility awareness-based methods, including the sympto-thermal method that tracks basal body temperature, cervical mucus, and cycle length, can be highly effective when learned properly and practiced consistently, though they require more engagement and carry higher failure rates with typical use than hormonal or IUD methods.

These options are not superior for every woman. They are worth knowing about for women who are weighing their options with full information.

What This Means for the Informed Patient

The most important thing the research on birth control and breast cancer supports is not any particular contraceptive decision. It is informed consent. Women deserve access to the actual findings, the actual numbers, and the actual nuances, including the formulation differences, the duration effects, the reversibility of elevated risk after stopping, and the protective benefits on other cancer types, so that they can make decisions that reflect their own values, baseline risk, and circumstances.

The risk is real and worth knowing. It is also genuinely small for most women at average baseline risk, reversible, formulation-dependent, and must be weighed against meaningful protective effects on other serious conditions. For women with elevated family history, BRCA mutations, or other risk factors, the conversation warrants more specific clinical attention.

What women do not deserve is either dismissal, the breezy reassurance that there is nothing to worry about, or alarm, the TikTok-era simplification that birth control causes cancer. The research lives between those two poles. And that is precisely where the conversation should also live.

If this is something you are navigating, bring these specific questions to your doctor or gynecologist: what formulation am I currently on, what is my personal baseline breast cancer risk, and what non-hormonal alternatives might be appropriate for my situation. Those questions, informed by the research, are the most useful place to start.

Scientific Sources

1. Hadizadeh, F., et al. Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women. JAMA Oncology, 2025.
2. Fitzpatrick, D., et al. Combined and Progestagen-Only Hormonal Contraceptives and Breast Cancer Risk: A UK Nested Case-Control Study and Meta-Analysis. PLOS Medicine, 2023.
3. ScienceDirect. Effect of Duration of Hormonal Contraceptive Use on Breast Cancer Risk: A Systematic Review and Meta-Analysis of Cohort Studies. 2025.
4. Torres-de la Roche, L.A., et al. Hormonal Contraception and the Risk of Breast Cancer in Women of Reproductive Age: A Meta-Analysis. Cancers, 2023.
5. PMC. Hormonal Contraception and Risk of Breast Cancer and Breast Cancer In Situ Among Swedish Women 15 to 34 Years of Age: A Nationwide Register-Based Study. 2022.
6. Susan G. Komen. Breast Cancer Risk: Birth Control Pills. komen.org, 2026.
7. BreastCancer.org. Does Hormonal Birth Control Increase the Risk of Breast Cancer? breastcancer.org, 2026.
8. KFF Health News. Breast Cancer and Birth Control: A Huge New Study Shows How Science Can Be Distorted. kffhealthnews.org, 2025.
9. CBS News. Huge New Study on Breast Cancer and Birth Control Shows How Science Can Be Distorted. cbsnews.com, 2025.
10. Contemporary OB/GYN. Contemporary Understanding of Breast Cancer Risk with Combined Oral Contraceptives. contemporaryobgyn.net, 2026.
11. Image: unknown